Showing results (11-20 of 19) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Science Translational Medicine|March 20, 2015
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanomaSiwen Hu-Lieskovan, Stephen Mok, Blanca Homet Moreno, et al.Cancer Immunology, Immunotherapy : CII|September 23, 2008
Immunosensitization with a Bcl-2 small molecule inhibitorJonathan Begley, Dan D Vo, Lilah F Morris, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2011
CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humansRong Rong Huang, Jason Jalil, James S Economou, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2014
CTLA4 blockade broadens the peripheral T-cell receptor repertoireLidia Robert, Jennifer Tsoi, Xiaoyan Wang, et al.The Journal of Clinical Investigation|March 5, 2013
Host immunity contributes to the anti-melanoma activity of BRAF inhibitorsDeborah A Knight, Shin Foong Ngiow, Ming Li, et al.Molecular Cancer|April 21, 2012
Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell linesErika von Euw, Mohammad Atefi, Narsis Attar, et al.Cancer Research|October 29, 2009
Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824Dan D Vo, Robert M Prins, Jonathan L Begley, et al.Journal of Translational Medicine|April 22, 2010
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032Jonas N Søndergaard, Ramin Nazarian, Qi Wang, et al.The New England Journal of Medicine|January 20, 2012
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitorsFei Su, Amaya Viros, Carla Milagre, et al.Pageof 2